Candel Therapeutics reports Q3 loss and $203.1 million in cash
Candel Therapeutics reported higher year-over-year losses for Q3 2026, with cash and equivalents of $203.1 million at September 30. The company expects its cash to support operations into Q2 2028. Candel said it is discussing with the FDA the requirements for a prostate-cancer biologics license application, which it currently aims to file in mid-2027 pending those discussions.
Why it matters
The reported cash balance and company outlook indicate funding coverage into Q2 2028 under its current operating plan. The planned mid-2027 filing would mark a regulatory milestone for Candel's aglatimagene program, but remains subject to FDA discussions and assay-refinement timing.
Key facts
- 1Cash and cash equivalents were $203.1 million at September 30, 2026, versus $119.7 million at December 31, 2025. tradingview.com
- 2Research and development expense rose to $15.6 million in Q3 2026 from $8.5 million in Q3 2025. tradingview.com
- 3General and administrative expense increased to $7.4 million from $4.7 million a year earlier. tradingview.com
- 4Candel plans to submit the prostate-cancer application in mid-2027, contingent on the outcome of its FDA discussions. tradingview.com
- 5The repeat-administration cohort in the linoserpaturev recurrent high-grade glioma study had median overall survival of 14.3 months, with follow-up still immature. tradingview.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.